Trial reportThe Journal of allergy and clinical immunology2019
Predicting development of sustained unresponsiveness to milk oral immunotherapy using epitope-specific antibody binding profiles.
Trial report in The Journal of allergy and clinical immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04100122 (Luminex-based Assay to Identify Major IgE-binding Episode Among IgE-mediated Wheat-allergic Patient), which is not on this map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Luminex-based Assay to Identify Major IgE-binding Episode Among IgE-mediated Wheat-allergic Patient
Who cites it
39 citing papers in PubMed.
- Baseline epitope-specific IgE profiles are predictive of sustained unresponsiveness or high threshold 1-year post oral immunotherapy in the POISED trial.The Journal of allergy and clinical immunology · 2025Trial
- Epitope-Specific IgE at 1 Year of Age Can Predict Peanut Allergy Status at 5 Years.International archives of allergy and immunology · 2023Trial
- CD8Nature communications · 2022Trial
- Trial
- Bioengineering Interventions to Enhance the Capacity of the Gut Microbiota in Controlling Food Allergies.Life (Basel, Switzerland) · 2026Review
- Advanced immunotherapy across diseases and the role of artificial intelligence: A review.Biomolecules & biomedicine · 2026Review
- Innovative diagnostic techniques and their clinical implications in food allergy: current clinical practice and future perspectives.Frontiers in allergy · 2026Review
- Gut mucosal immune responses - Implications for celiac disease and food allergy.Seminars in immunology · 2025Review
- Diagnostic Usefulness of Detecting IgE Content and Profile Specific to 14 Epitopes Defined in Cow's Milk Allergen.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2025Article
- Epitope-Specific Antibodies in Allergic Disease and Clinical Tolerance.Immunological reviews · 2025Review
- Biomarker-driven drug development for allergic diseases and asthma: An FDA public workshop.The Journal of allergy and clinical immunology · 2025Article
- Molecular Diagnosis to IgE-mediated Wheat Allergy and Wheat-Dependent Exercise-Induced Anaphylaxis.Clinical reviews in allergy & immunology · 2025Review
- Emerging diagnostic and therapeutic opportunities in food allergy.Frontiers in immunology · 2025Review
- Long-term efficacy and safety of cow's milk anaphylaxis specific immunotherapy: Allergen unresponsiveness via the Tolerance Induction Program.The journal of allergy and clinical immunology. Global · 2024Article
- Engineering therapeutic monoclonal antibodies.The Journal of allergy and clinical immunology · 2024Review
- The future of food allergy diagnosis.Frontiers in allergy · 2024Review
- Targeting type 2 immunity and the future of food allergy treatment.The Journal of experimental medicine · 2023Review
- Human Monoclonal IgE Antibodies-a Major Milestone in Allergy.Current allergy and asthma reports · 2023Review
- IgE and IgG4 Epitope Mapping of Food Allergens with a Peptide Microarray Immunoassay.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Mechanisms and biomarkers of successful allergen-specific immunotherapy.Asia Pacific allergy · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundIn a recent trial of milk oral immunotherapy (MOIT) with or without omalizumab in 55 patients with milk allergy treated for 28 months, 44 of 55 subjects passed a 10-g desensitization milk protein challenge; 23 of 55 subjects passed the 10-g sustained unresponsiveness (SU) challenge 8 weeks after discontinuing MOIT.
objectiveWe sought to determine whether IgE and IgG
methodsBy using a novel high-throughput Luminex-based assay to quantitate IgE and IgG
resultsMOIT profoundly altered IgE and IgG
conclusionDespite the relatively small sample size, we have shown that by measuring the epitope repertoire, we can build reliable models to predict the probability of SU after MOIT. Baseline epitope profiles appear more predictive of MOIT response than those based on serum component proteins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.